PBA
LEGN icon

Paradigm Biocapital Advisors’s Legend Biotech LEGN Stock Holding History

Paradigm Biocapital Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,203,308
Closed -$53.3M – 38
2024
Q2 		$53.3M Sell
1,203,308
-778,698
-39% -$35.9M 2.04% 17
2024
Q1 		$111M Buy
1,982,006
+87,362
+5% +$5.27M 3.91% 8
2023
Q4 		$114M Sell
1,894,644
-130,836
-6% -$8.29M 5.34% 5
2023
Q3 		$136M Buy
2,025,480
+219,763
+12% +$15.3M 9.23% 1
2023
Q2 		$125M Buy
1,805,717
+295,393
+20% +$19.3M 9.63% 1
2023
Q1 		$72.8M Buy
1,510,324
+455,454
+43% +$22.3M 6.9% 3
2022
Q4 		$52.7M Sell
1,054,870
-21,721
-2% -$1.05M 6.18% 5
2022
Q3 		$43.9M Buy
1,076,591
+97,995
+10% +$4.6M 5.86% 5
2022
Q2 		$53.8M Buy
978,596
+146,868
+18% +$6.2M 10.73% 1
2022
Q1 		$30.2M Buy
831,728
+445,761
+115% +$17.6M 7.99% 4
2021
Q4 		$18M Buy
+385,967
New +$19.6M 5.14% 8

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Paradigm Biocapital Advisors's LEGN Position: Q3 2024 in Review

Paradigm Biocapital Advisors sold out of Legend Biotech (LEGN) in Q3 2024, closing a stake of 1,203,308 shares — an estimated $53.3M sold.

Paradigm Biocapital Advisors first reported a position in LEGN in Q4 2021 and held it in 11 quarters. The position peaked at $136M in Q3 2023. 208 funds tracked by Wall St. Rank hold LEGN as of Q3 2024.

  • Paradigm Biocapital Advisors reported no remaining Legend Biotech position as of Q3 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,203,308 Legend Biotech shares in Q3 2024, an estimated $53.3M.
  • Paradigm Biocapital Advisors first reported a position in Legend Biotech in Q4 2021 and held it in 11 quarters.
  • Paradigm Biocapital Advisors's Legend Biotech position peaked at $136M in Q3 2023.
  • 208 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.